Our contribution to understanding the pathological mechanism of AAT aggregation in liver tissue opens prospects for therapeutic strategies to target the polymerization pathway that underlies not only AATD but also potentially other aggregation-induced serpinopathies. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.